The administration of recombinant forms of cerebral dopamine neurotrophic factor (CDNF) or MANF post-stroke has been shown to enhance recovery of neurological function, presenting a promising therapeutic strategy for addressing stroke-induced limb dysfunctions [76]. The gene discussed is MANF; the disease is Stroke.